多替拉韦与抗疟药联用的群体药代动力学研究
本研究利用26名健康志愿者的403份多替拉韦稳态血药浓度数据建立群体药代动力学模型,评估与蒿甲醚/苯芴醇或青蒿琥酯/阿莫地喹联用对多替拉韦清除率的影响。结果显示联用使多替拉韦清除率分别增加10.6%和26.4%,但模拟谷浓度仍高于蛋白校正IC90,提示无需调整剂量。
要点
- 与蒿甲醚/苯芴醇或青蒿琥酯/阿莫地喹联用使多替拉韦清除率分别增加10.6%和26.4%。
- 模拟谷浓度在超过99%的个体中维持在蛋白校正IC90(0.064 mg/L)以上。
- 服用标准3天疗程抗疟药时,多替拉韦无需调整剂量。
核心结论
- 与标准3天疗程的蒿甲醚/苯芴醇或青蒿琥酯/阿莫地喹联用时,多替拉韦无需调整剂量。
研究设计与样本
- 基于26名健康志愿者的两项2期研究数据,共403份多替拉韦稳态血药浓度,建立群体药代动力学模型。
主要发现
- 多替拉韦清除率典型值为0.713 L/h,吸收速率常数1.68 h⁻¹,中央室体积13.2 L,外周室体积5.73 L,平均吸收转运时间1.18 h。
- 联用蒿甲醚/苯芴醇使多替拉韦清除率增加10.6%(95% CI 4.09%-34.5%)。
- 联用青蒿琥酯/阿莫地喹使多替拉韦清除率增加26.4%(95% CI 14.3%-51.4%)。
- 模拟显示单用或联用时,超过99%的个体多替拉韦谷浓度维持在0.064 mg/L以上。
关键数值与推荐
- 多替拉韦给药方案为50 mg每日一次,单用或联用蒿甲醚/苯芴醇(80/480 mg)或青蒿琥酯/阿莫地喹(200/540 mg)标准治疗剂量。
- 多替拉韦蛋白校正IC90为0.064 mg/L。
临床怎么用
- 在需要联用蒿甲醚/苯芴醇或青蒿琥酯/阿莫地喹抗疟治疗时,可维持多替拉韦标准剂量不变。
局限性
- 研究仅纳入26名健康志愿者,未覆盖患者群体及长期联用情况。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In sub-Saharan Africa, artemisinin-containing therapies for malaria treatment are regularly co-administered with ART. Currently, dolutegravir-based regimens are recommended as first-line therapy for HIV across most of Africa. OBJECTIVES: To investigate the population pharmacokinetics of dolutegravir during co-administration with artemether/lumefantrine or artesunate/amodiaquine, two commonly used antimalarial therapies. METHODS: We developed a population pharmacokinetic model of dolutegravir with data from 26 healthy volunteers in two Phase 2 studies with a total of 403 dolutegravir plasma concentrations at steady state. Volunteers received 50 mg of dolutegravir once daily alone or in combination with standard treatment doses of artemether/lumefantrine (80/480 mg) or artesunate/amodiaquine (200/540 mg). RESULTS: A two-compartment model with first-order elimination and transit compartment absorption best described the concentration-time data of dolutegravir. Typical population estimates for clearance, absorption rate constant, central volume, peripheral volume and mean absorption transit time were 0.713 L/h, 1.68 h-1, 13.2 L, 5.73 L and 1.18 h, respectively. Co-administration of artemether/lumefantrine or artesunate/amodiaquine increased dolutegravir clearance by 10.6% (95% CI 4.09%-34.5%) and 26.4% (95% CI 14.3%-51.4%), respectively. Simulations showed that simulated trough concentrations of dolutegravir alone or in combination with artemether/lumefantrine or artesunate/amodiaquine are maintained above the dolutegravir protein-adjusted IC90 of 0.064 mg/L for more than 99% of the individuals. CONCLUSIONS: Dolutegravir dose adjustments are not necessary for patients who are taking standard 3 day treatment doses of artemether/lumefantrine or artesunate/amodiaquine.
引用
- Kawuma AN, Walimbwa SI, Pillai GC, et al. Dolutegravir pharmacokinetics during co-administration with either artemether/lumefantrine or artesunate/amodiaquine. J Antimicrob Chemother. 2021. PMID: 33550391. doi:10.1093/jac/dkab022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。